- Cash and cash equivalents of €9.2m at 31 December
2020
- Focus on the valuation of CER-001 in severe kidney
diseases
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today announces its annual results for the financial year ending 31
December 2020 and provides an update on activity to date. Audit
procedures on the consolidated financial statements have been
carried out. The certification report will be issued after
completion of the procedures required for the filing of the
universal registration document.
Selected financial information
(as of 31 December 2020/Consolidated financial statements under
IFRS)
Millions €
2020
2019
Revenue
0
0
R&D expenditures
-1.7
-0.7
Administrative, sales and marketing
expenses
-1.3
-1.8
Operating income
-3.0
-2.5
Financial income
1.2
4.8
Financial expense
-0.1
-0.4
Net financial items
1.1
4.4
Net income
-1.9
1.8
Net cash flows related to operating
activities
-0.6
-3.9
Net cash flow from investing
activities
-0.1
0.0
Net cash flows related to financing
activities
1.5
0.8
Cash position variation
0.8
-3.1
Cash and cash equivalents at the end of
the period
9.2
8.3
Details of the main changes in the consolidated financial
statements
As ABIONYX Pharma's activities are dedicated to the discovery
and development of innovative therapies to improve the lives of
patients, the company did not generate any revenues in the
financial year 2020.
Research and development expenses amounted to €1,698 K
over the period, compared to €744 K for the financial year 2019.
This level of expenditure includes the initial costs relating to
the new CER-001 production campaign and costs related to
exploratory studies for the valuation of its existing assets.
General and administrative expenses amounted to €1,270 K
in 2020 compared to €1,781 K the previous year. The decrease is
mainly due to lower fees and continued efforts to control current
expenses.
After taking all these factors into account, operating
profit fell from a loss of €2,525 K at 31 December 2019 to a
loss of €2,968 K at 31 December 2020.
Following Bpifrance's debt waiver following the total technical
failure of the CER-209 project for which a repayable advance had
been granted, financial income of €900 K was recognised in December
2020. Financial income thus amounted to €1,082 K at December
31, 2020, compared with €4,412 K at December 31, 2019.
The net result was a loss of €1,886 K at 31 December 2020
compared with a profit of €1,849 K at 31 December 2019.
Cash and cash equivalents amounted to €9,154 K at 31 December
2020, compared with €8,331 K at 31 December 2019. The Company
obtained the repayment of the 2018 and 2019 CIRs for a cumulative
amount of €1,725 K, to which was added the amount of €1,860 K
following the capital increase of October 2020.
Key highlights in 2020
In 2020, the company decided to focus on the valuation of
CER-001, which is proving to be of interest for short-term
treatments and severe indications, mainly renal at the moment.
In early 2020, the French National Agency for Drug Safety (ANSM)
granted a Temporary Authorisation for Named Use (ATUn) for CER-001
in an ultra-rare kidney disease for which existing treatments are
proving insufficient. In February 2020, a new Temporary
Authorisation for Named Use (ATUn) for CER‑001 was granted in Italy
for an ultra-rare kidney disease for which existing treatments are
proving to be insufficient.
Given the availability of stocks of CER-001, ABIONYX Pharma has
committed to supply the product free of charge over a period of
three months under these two ATUns. In order to respond to possible
new ATUn requests, the company carried out a capital increase of
around €1,860 K (including the premium) intended to strengthen the
company's cash position with a view to launching a new production
campaign for CER-001, a mimetic HDL which is a biological product.
This new campaign is accompanied by a relocation of production to
France.
In the last quarter of 2020, the company received authorisation
from the Italian regulatory authorities to initiate the start of a
new phase 2a clinical study for CER-001, called RACERS, in patients
with septicaemia at high risk of developing acute kidney damage, in
partnership with the University of Bari.
This study follows the positive therapeutic signals found in
nATUs in France and Italy in ultra-rare kidney disease and the
positive preclinical results announced in the journal Metabolism on
15 December, which demonstrate that CER-001 improves renal
function. The study is fully funded with current assets was
designed with key support from Italian Key Opinion Leaders from the
University of Bari and will be managed with the CBVF
consortium.
The overall preclinical results and clinical signals point to
the efficacy of CER-001 in kidney disease and a potentially
modifying effect on the progression of the inflammatory cascade in
septicaemia. They mark the repositioning of CER-001 in severe renal
diseases that have not seen a breakthrough innovation for a long
time. The company is awaiting further preclinical and clinical
results.
Next press release: Cash
position and activity update for Q1 2021, May 6, 2021
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients.
The biotech assets inherited from CERENIS Therapeutics constitute a
rich portfolio of valuable programs for the treatment of metabolic
diseases as well as with a HDL targeted drug delivery platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005980/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024